Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.77 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.77 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | SELP | P16109 | 1/20 | 0.73 |
| ▸ | FABP3 | P05413 | 1/20 | 0.73 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.67 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.67 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.67 |
| ▸ | P2RY10 | O00398 | 3/20 | 0.67 |
| ▸ | GPR174 | Q9BXC1 | 3/20 | 0.67 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.67 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366943 | 1.00 | LPAR3 (0.77) | LPAR3LPAR1ENPP2SMN1; SMN2SELP | |
| SCHEMBL29370136 | 1.00 | LPAR3 (0.77) | LPAR3LPAR1ENPP2SMN1; SMN2SELP | |
| SCHEMBL29410385 | 1.00 | LPAR3 (0.77) | LPAR3LPAR1ENPP2SMN1; SMN2SELP | |
| SCHEMBL30892361 | 1.00 | LPAR3 (0.77) | LPAR3LPAR1ENPP2SMN1; SMN2SELP | |
| SCHEMBL29366847 | 1.00 | LPAR3 (0.77) | LPAR3LPAR1ENPP2SMN1; SMN2SELP | |
| SCHEMBL32662595 | 1.00 | LPAR3 (0.77) | LPAR3LPAR1ENPP2SMN1; SMN2SELP | |
| SCHEMBL31591262 | 1.00 | LPAR3 (0.77) | LPAR3LPAR1ENPP2SMN1; SMN2SELP | |
| SCHEMBL30898878 | 1.00 | LPAR3 (0.77) | LPAR3LPAR1ENPP2SMN1; SMN2SELP | |
| SCHEMBL40385 | 1.00 | LPAR3 (0.77) | LPAR3LPAR1ENPP2SMN1; SMN2SELP | |
| SCHEMBL29369405 | 1.00 | LPAR3 (0.77) | LPAR3LPAR1ENPP2SMN1; SMN2SELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100323000-A1 | METHOD AND PROCESS FOR PREPARING CARDIOLIPIN | NEOPHARM, INC. (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323000-A1 | METHOD AND PROCESS FOR PREPARING CARDIOLIPIN | PHOSPHO1, SGMS1, SGMS2 | LPAR3 144/4885LPAR1 102/4885ENPP2 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.